Pessary Self-Management Versus Clinical Management in Women With Pelvic Organ Prolapse: A Prospective Multicenter Cohort Study

Börger R1, Steures P2, Daanen M1, Koppes D1, van der Vlist M3, Overbeek A4, Pleunis N5, Engberts M6, van Leijsen S7, Maas J8, Weemhoff M1

Research Type

Clinical

Abstract Category

Conservative Management

Abstract 9
Female LUTS
Scientific Podium Short Oral Session 2
Wednesday 7th October 2026
09:30 - 09:37
Parallel Hall 3
0.4 Brussels / 0.5 Paris
Capacity: 356
Conservative Treatment Pelvic Organ Prolapse Prospective Study Female
1. Zuyderland Medical Centre, 2. Jeroen Bosch Medical Centre, 3. Albert Schweitzer Medical Centre, 4. Noordwest Medical Centre, 5. Rijnstate Medical Centre, 6. Isala Medical Centre, 7. Maxima Medical Centre, 8. Maastricht University Medical Centre
Presenter
Links

Abstract

Hypothesis / aims of study
Pelvic organ prolapse (POP) is common among aging women. Up to 50% have some degree of POP, while six to eight percent experience symptoms. With an aging population, the prevalence of POP is expected to increase, leading to additional demands on already strained healthcare systems. 
Pessary treatment is a cost-effective treatment for POP, but is often discontinued because of side effects such as vaginal discharge, vaginal blood loss due to decubitus, discomfort, and intercourse related problems [1].
Traditional clinical management (CM) which involves regular removal, cleaning, and reinsertion of the pessary by a healthcare professional, burdens healthcare services and may be inconvenient for patients [2].
Therefore, interest in pessary self-management (PSM), in which patients manage their pessary independently has increased. PSM may improve healthcare sustainability and patient autonomy and satisfaction [3].
The aim of this study was to investigate whether PSM is superior to CM regarding side effects after 12 months of pessary treatment We also evaluated treatment continuation, crossover to surgery, and number of consultations in the first year after treatment initiation.
Study design, materials and methods
A prospective cohort study was conducted in seven Dutch medical centres between 2023 and 2025. Patients with POP for whom a PSM-suitable pessary (ring, ring with knob, ring with support) was fitted were included. Cube pessaries were excluded as they are PSM-only. All patients were offered PSM training by a specialist nurse. Data on patient characteristics were obtained from the electronic health record. Patients received questionnaires at baseline, six weeks and 12 months after treatment initiation. Questionnaires contained disease-specific questions, side effects (e.g. vaginal discharge, decubitus related blood loss, pain/discomfort, intercourse difficulties), and treatment continuation. Independent samples t-tests, chi-square tests, and logistic regression analyses were performed to compare groups and identify factors associated with treatment continuation.
Results
Of 301 included patients, 249 opted for PSM of whom 208 (84%) successfully learned self-management. Women in the PSM group were younger (61 vs. 69 p <0.001) and had a lower BMI (24.6 vs. 25.9 p = 0.01) compared with the women in de CM group.
At 12 months, there was no difference in side effects between the groups, treatment continuation was high and crossover to surgery was low in both groups. The number of physician consultations was significantly lower in the PSM group compared with the CM group (Table 1).
In the PSM group pain/discomfort was associated with discontinuation of treatment (Table 2). In the CM group, vaginal discharge and intercourse difficulties were associated with discontinuation in both univariable and multivariable analyses (Table 2).
Interpretation of results
PSM is a feasible and comparable alternative to CM. Although no difference in side effects was observed between the groups, the CM group required a higher number of physician consultations than the PSM group, a finding with important implications for reducing the burden on healthcare services.
Intercourse related problems and vaginal discharge were associated with treatment discontinuation in the CM group. These associations were not observed in the PSM group. This may be explained by the ability of women in the PSM group to temporarily remove the pessary when experiencing discharge or intercourse difficulties.
Concluding message
PSM had an 83% success rate among those willing to learn. Side effects, treatment continuation, and crossover to surgery were similar between groups, but the number of physician consultations was significantly lower in the PSM group. Pain/discomfort was associated with discontinuation in the PSM group, whereas vaginal discharge and intercourse difficulties did so in the CM group.
Figure 1 Table 1. Side effects and treatment results, PSM vs. CM. SD standard deviation, n number. AIn 12 months after start of PSM and after a fitted pessary in CM. *Fisher’s Exact test.
Figure 2 Table 2. Pessary treatment discontinuation vs. continuation in the pessary self-management group and the clinical management group. SD standard deviation, n number, CI confidence interval. *Fisher’s Exact test.
References
  1. Sarma S, Ying T, Moore KH. Long-term vaginal ring pessary use: discontinuation rates and adverse events. BJOG. 2009 Dec;116(13):1715-21. doi: 10.1111/j.1471-0528.2009.02380.x. PMID: 19906018.
  2. Hagen S, Kearney R, Goodman K, Best C, Elders A, Melone L, Dwyer L, Dembinsky M, Graham M, Agur W, Breeman S, Culverhouse J, Forrest A, Forrest M, Guerrero K, Hemming C, Khunda A, Manoukian S, Mason H, McClurg D, Norrie J, Thakar R, Bugge C. Clinical effectiveness of vaginal pessary self-management vs clinic-based care for pelvic organ prolapse (TOPSY): a randomised controlled superiority trial. EClinicalMedicine. 2023 Nov 23;66:102326. doi: 10.1016/j.eclinm.2023.102326. PMID: 38078194;
  3. Stairs J, Gujral P, Ehlebracht A, van Diepen A, Clancy AA. Women's attitudes towards pessary self-care: a qualitative study. Int Urogynecol J. 2023 Aug;34(8):1899-1906. doi: 10.1007/s00192-023-05472-x. Epub 2023 Feb 16. PMID: 36795110; PMCID: PMC9933032.
Disclosures
Funding This study was funded by mProve, a partnership between seven Dutch medical centres. Clinical Trial Yes Registration Number ClinicalTrials.gov Z2022098 RCT No Subjects Human Ethics Committee METZ Helsinki Yes Informed Consent Yes AI Not at all
Citation

Continence 19S (2026) 102486
DOI: 10.1016/j.cont.2026.102486

24/10/2026 06:44:47